PE20191614A1 - Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo - Google Patents
Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandoloInfo
- Publication number
- PE20191614A1 PE20191614A1 PE2019001541A PE2019001541A PE20191614A1 PE 20191614 A1 PE20191614 A1 PE 20191614A1 PE 2019001541 A PE2019001541 A PE 2019001541A PE 2019001541 A PE2019001541 A PE 2019001541A PE 20191614 A1 PE20191614 A1 PE 20191614A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- cognitive disorders
- treat
- antibody
- prevent cognitive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a un anticuerpo anti fosforilado anti-pSer413 tau, el cual se une a la proteina tau fosforilada en el residuo de serina 413, que comprende: a) un dominio variable pesado seleccionado de SEQ ID NO: 116 y SEQ ID NO: 117; b) un dominio variable ligero seleccionado de SEQ ID NO: 114, SEQ ID NO: 104, entre otras; c) un dominio constante pesado seleccionado de SEQ ID NO: 135, SEQ ID NO: 136, entre otras y d) un dominio constante ligero seleccionado entre SEQ ID NO: 79 y SEQ ID NO: 80. Ademas se refiere a una composicion de acido nucleico que comprende: a) un primer acido nucleico que codifica una cadena ligera seleccionada de SEQ ID NO: 162, SEQ ID NO: 163, entre otras; y b) un segundo acido nucleico que codifica una cadena pesada seleccionada de SEQ ID NO: 144; SEQ ID NO: 145, entre otras; un vector, una celula huesped que codifica dicho anticuerpo y una composicion farmaceutica que comprende dicho anticuerpo. Dicho anticuerpo tiene una afinidad selectiva con la proteina tau fosforilada y presenta antigenicidad reducida para el cuerpo humano, siendo util para el tratamiento de trastornos cognitivos, como la enfermedad del Alzheimer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017035594A JP2018139530A (ja) | 2017-02-27 | 2017-02-27 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| PCT/IB2018/000249 WO2018154390A1 (en) | 2017-02-27 | 2018-02-27 | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191614A1 true PE20191614A1 (es) | 2019-11-05 |
Family
ID=62025891
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001024A PE20241514A1 (es) | 2017-02-27 | 2018-02-27 | Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo |
| PE2019001541A PE20191614A1 (es) | 2017-02-27 | 2018-02-27 | Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001024A PE20241514A1 (es) | 2017-02-27 | 2018-02-27 | Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10556950B2 (es) |
| EP (1) | EP3585810B1 (es) |
| JP (4) | JP2018139530A (es) |
| KR (1) | KR102701634B1 (es) |
| CN (2) | CN111320695B (es) |
| AR (2) | AR110875A1 (es) |
| AU (1) | AU2018224390C1 (es) |
| BR (1) | BR112019016490A2 (es) |
| CA (1) | CA3052538A1 (es) |
| CL (3) | CL2019002296A1 (es) |
| CO (1) | CO2019008786A2 (es) |
| CR (1) | CR20190363A (es) |
| DO (1) | DOP2019000215A (es) |
| EA (1) | EA201991726A1 (es) |
| GE (1) | GEP20227392B (es) |
| IL (1) | IL267945B2 (es) |
| JO (1) | JOP20180014A1 (es) |
| MA (1) | MA47608A (es) |
| MX (2) | MX2019009945A (es) |
| MY (1) | MY193821A (es) |
| NI (1) | NI201900086A (es) |
| PE (2) | PE20241514A1 (es) |
| PH (1) | PH12019501929A1 (es) |
| SG (2) | SG11201907548PA (es) |
| TW (2) | TW202506718A (es) |
| WO (2) | WO2018154392A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013268364B2 (en) * | 2012-05-31 | 2018-02-08 | Osaka City University | Therapeutic agent or prophylactic agent for dementia |
| BR112019017021A2 (pt) | 2017-02-17 | 2020-04-14 | Denali Therapeutics Inc | anticorpos anti-tau e métodos de uso dos mesmos |
| JOP20180014A1 (ar) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
| PE20212088A1 (es) | 2017-10-16 | 2021-11-04 | Eisai Randd Man Co Ltd | Anticuerpos anti-tau y uso de los mismos |
| US20210355199A1 (en) | 2018-06-28 | 2021-11-18 | University Of Virginia Patent Foundation | Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling |
| US12365724B2 (en) * | 2018-12-10 | 2025-07-22 | New York University | Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof |
| WO2020167789A1 (en) | 2019-02-11 | 2020-08-20 | University Of Virginia Patent Foundation | Selection and blockade of fertilization competent male and female gametes |
| WO2020186247A1 (en) | 2019-03-13 | 2020-09-17 | University Of Virginia Patent Foundation | Compositions and methods for promoting islet viability and enhancing insulin secretion |
| TWI832183B (zh) * | 2019-08-06 | 2024-02-11 | 香港商新旭生技股份有限公司 | 結合至病理性tau種類之抗體及其用途 |
| EP4159860A4 (en) * | 2020-06-02 | 2024-09-25 | Teijin Pharma Limited | HUMANIZED ANTI-IGF-1 RECEPTOR ANTIBODY |
| CA3183835A1 (en) * | 2020-06-25 | 2021-12-30 | Jeanne E. Baker | High affinity antibodies targeting tau phosphorylated at serine 413 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN115322255B (zh) * | 2022-04-25 | 2025-03-07 | 上海药明生物医药有限公司 | 一种优化的Fc变体及其应用 |
| CN120019071A (zh) | 2022-09-15 | 2025-05-16 | 沃雅戈治疗公司 | Tau结合化合物 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN119080924B (zh) * | 2024-07-04 | 2025-02-25 | 上海交通大学医学院附属第九人民医院 | 一种单克隆免疫球蛋白及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS587390B2 (ja) | 1975-03-11 | 1983-02-09 | ツキシマキカイ カブシキガイシヤ | ア−クヨウセツホウホウ |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JP3587390B2 (ja) | 1994-03-17 | 2004-11-10 | タカラバイオ株式会社 | リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法 |
| WO2005022156A1 (ja) | 2003-08-29 | 2005-03-10 | Reverse Proteomics Research Institute Co., Ltd. | タンパク質の固定化方法 |
| EP2221315A1 (en) | 2003-12-04 | 2010-08-25 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| DK2625198T3 (en) | 2010-10-07 | 2015-09-28 | Ac Immune Sa | Antibodies that recognize the phosphorylated tau |
| HRP20181320T8 (hr) | 2010-10-11 | 2018-12-14 | Biogen International Neuroscience Gmbh | Ljudska anti-tau protutijela |
| CN107226863B (zh) | 2011-12-20 | 2021-06-01 | 詹森生物科技公司 | 抗PHF-tau抗体及其用途 |
| AU2013268364B2 (en) * | 2012-05-31 | 2018-02-08 | Osaka City University | Therapeutic agent or prophylactic agent for dementia |
| NZ630542A (en) * | 2012-08-16 | 2017-06-30 | Ipierian Inc | Methods of treating a tauopathy |
| BR112015014751A8 (pt) | 2012-12-21 | 2018-01-16 | Biogen Int Neuroscience Gmbh | anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos. |
| CA2914768A1 (en) | 2013-06-10 | 2014-12-18 | Ipierian, Inc. | Methods of treating a tauopathy |
| EP3083680B1 (en) | 2013-12-20 | 2020-01-15 | F. Hoffmann-La Roche AG | Humanized anti-tau(ps422) antibodies and methods of use |
| AR100978A1 (es) * | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| TWI664190B (zh) * | 2014-06-27 | 2019-07-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗－ｔａｕ抗體 |
| KR20170080675A (ko) | 2014-11-05 | 2017-07-10 | 제넨테크, 인크. | 항-fgfr2/3 항체 및 이의 이용 방법 |
| WO2016112078A2 (en) | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
| CA2991451A1 (en) | 2015-07-06 | 2017-01-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| EP3319984A1 (en) | 2015-07-06 | 2018-05-16 | UCB Biopharma SPRL | Tau-binding antibodies |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| JOP20180014A1 (ar) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
-
2017
- 2017-02-27 JO JOP/2018/0014A patent/JOP20180014A1/ar unknown
- 2017-02-27 JP JP2017035594A patent/JP2018139530A/ja active Pending
-
2018
- 2018-02-25 WO PCT/IB2018/000267 patent/WO2018154392A1/en not_active Ceased
- 2018-02-26 TW TW113125487A patent/TW202506718A/zh unknown
- 2018-02-26 TW TW107106444A patent/TWI848904B/zh active
- 2018-02-27 WO PCT/IB2018/000249 patent/WO2018154390A1/en not_active Ceased
- 2018-02-27 MA MA047608A patent/MA47608A/fr unknown
- 2018-02-27 CR CR20190363A patent/CR20190363A/es unknown
- 2018-02-27 MY MYPI2019004787A patent/MY193821A/en unknown
- 2018-02-27 BR BR112019016490A patent/BR112019016490A2/pt unknown
- 2018-02-27 CN CN202010117151.0A patent/CN111320695B/zh active Active
- 2018-02-27 EP EP18718907.1A patent/EP3585810B1/en active Active
- 2018-02-27 AR ARP180100454A patent/AR110875A1/es unknown
- 2018-02-27 GE GEAP201815170A patent/GEP20227392B/en unknown
- 2018-02-27 JP JP2019545918A patent/JP7165996B2/ja active Active
- 2018-02-27 CN CN201880008302.XA patent/CN110382528A/zh active Pending
- 2018-02-27 PE PE2024001024A patent/PE20241514A1/es unknown
- 2018-02-27 SG SG11201907548PA patent/SG11201907548PA/en unknown
- 2018-02-27 EA EA201991726A patent/EA201991726A1/ru unknown
- 2018-02-27 SG SG10201913419TA patent/SG10201913419TA/en unknown
- 2018-02-27 CA CA3052538A patent/CA3052538A1/en active Pending
- 2018-02-27 KR KR1020197024146A patent/KR102701634B1/ko active Active
- 2018-02-27 US US15/906,773 patent/US10556950B2/en active Active
- 2018-02-27 PE PE2019001541A patent/PE20191614A1/es unknown
- 2018-02-27 MX MX2019009945A patent/MX2019009945A/es unknown
- 2018-02-27 AU AU2018224390A patent/AU2018224390C1/en active Active
-
2019
- 2019-07-09 IL IL267945A patent/IL267945B2/en unknown
- 2019-08-09 NI NI201900086A patent/NI201900086A/es unknown
- 2019-08-13 CO CONC2019/0008786A patent/CO2019008786A2/es unknown
- 2019-08-13 CL CL2019002296A patent/CL2019002296A1/es unknown
- 2019-08-15 DO DO2019000215A patent/DOP2019000215A/es unknown
- 2019-08-20 MX MX2023013246A patent/MX2023013246A/es unknown
- 2019-08-20 PH PH12019501929A patent/PH12019501929A1/en unknown
- 2019-08-22 AR ARP190102386A patent/AR117952A2/es unknown
-
2020
- 2020-01-17 US US16/746,725 patent/US10894829B2/en active Active
- 2020-12-15 US US17/122,325 patent/US11739143B2/en active Active
-
2021
- 2021-09-13 CL CL2021002389A patent/CL2021002389A1/es unknown
-
2022
- 2022-10-18 JP JP2022166859A patent/JP2023002670A/ja active Pending
-
2024
- 2024-02-02 CL CL2024000339A patent/CL2024000339A1/es unknown
- 2024-08-28 JP JP2024146101A patent/JP2024170459A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191614A1 (es) | Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo | |
| EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
| MX2020003190A (es) | Degradadores de proteinas y usos de los mismos. | |
| CY1122265T1 (el) | Αντισωματα εναντι ταυ και χρησεις αυτων | |
| MX2024015440A (es) | Anticuerpos anti-phf-tau y usos de estos | |
| WO2018017864A3 (en) | Pvrig-binding agents and uses thereof | |
| NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| MX383216B (es) | Anticuerpos dirigidos contra la inmunoglobulina de células t y la proteína mucina 3 (tim-3). | |
| WO2017134302A3 (en) | Targeted therapeutic agents and uses thereof | |
| CL2015002529A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| EA201992609A1 (ru) | Слитые белки, содержащие интерлейкин-2, и их применения | |
| EA201892561A1 (ru) | Гибридные белки gdf15 и их применение | |
| WO2016191643A3 (en) | Tigit-binding agents and uses thereof | |
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| EA202090720A1 (ru) | ПРОИЗВОДНЫЕ GalNAc | |
| PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
| EA201892548A1 (ru) | Антитела к альфа-синуклеину и их применение | |
| BR112013002831A2 (pt) | anticorpos direcionados contra a il-17 | |
| PE20180481A1 (es) | Anticuerpos de union a tau | |
| EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| EA202090401A1 (ru) | Анти-tim-3 антитела и их применение | |
| MX392158B (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
| MX2020009522A (es) | Anticuerpos anti-folato del receptor 1 y usos de los mismos. |